OBG3 globular head and uses thereof for decreasing body mass
View Patent ↗The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.
1. An isolated polynucleotide consisting of:
a) a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6; or
b) a nucleic acid sequence complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
2. The isolated polynucleotide according to claim 1 , wherein said nucleic acid sequence encodes consecutive amino acids 101 to 244 of SEQ ID NO:6.
3. The isolated polynucleotide according to claim 2 , wherein said nucleic acid sequence further comprise at least one additional heterologous nucleic acid sequence.
4. The isolated polynucleotide according to claim 3 , wherein said at least one additional heterologous nucleic acid sequence encodes a heterologous polypeptide.
5. The isolated polynucleotide according to claim 1 , wherein said nucleic acid sequence is complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
6. The isolated polynucleotide according to claim 5 , wherein said nucleic acid sequence further comprises at least one additional heterologous nucleic acid sequence.
7. A composition comprising a carrier and an isolated polynucleotide consisting of:
a) a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6; or
b) a nucleic acid sequence complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
8. The composition according to claim 7 , wherein said nucleic acid sequence encodes consecutive amino acids 101 to 244 of SEQ ID NO:6.
9. The composition according to claim 8 , wherein said nucleic acid sequence further comprises at least one additional heterologous nucleic acid sequence.
10. The composition according to claim 7 , wherein said nucleic acid sequence is complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
11. The composition according to claim 10 , wherein said nucleic acid sequence further comprises at least one additional heterologous nucleic acid sequence.
12. A vector comprising an isolated polynucleotide sequence consisting of:
a) a nucleic acid sequence encoding consecutive amino acids 101 to 244 or SEQ ID NO:6; or
b) a nucleic acid sequence complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
13. The vector according to claim 12 , wherein said nucleic acid sequence encodes consecutive amino acids 101 to 244 of SEQ ID NO:6.
14. The vector according to claim 13 , wherein said nucleic acid sequence further comprises at least one additional heterologous nucleic acid sequence.
15. The vector according to claim 14 , wherein said at least one additional heterologous nucleic acid sequence encodes a heterologous polypeptide.
16. The vector according to claim 12 , wherein said nucleic acid sequence is complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
17. The vector according to claim 16 , wherein said nucleic acid sequence further comprises at least one additional heterologous nucleic acid sequence.
18. A composition comprising a carrier and a vector comprising an isolated polynucleotide sequence consisting of:
a) a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6; or
b) a nucleic acid sequence complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
19. The composition according to claim 18 , wherein said nucleic acid sequence encodes consecutive amino acids 101 to 244 of SEQ ID NO:6.
20. The composition according to claim 19 , wherein said nucleic acid sequence further comprises at least one additional heterologous nucleic acid sequence.
21. The composition according to claim 20 , wherein said at least one additional nucleic acid sequence encodes a heterologous polypeptide.
22. The composition according to claim 18 , wherein said nucleic acid sequence is complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
23. The composition according to claim 22 , wherein said nucleic acid sequence further comprises at least one additional heterologous nucleic acid sequence.
24. A transformed host cell comprising a vector comprising an isolated polynucleotide sequence consisting of:
a) a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6; or
b) a nucleic acid sequence complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
25. The transformed host cell according to claim 24 , wherein said nucleic acid sequence encodes consecutive amino acids 101 to 244 of SEQ ID NO:6.
26. The transformed host cell according to claim 24 , wherein said nucleic acid sequence is complementary to a nucleic acid sequence encoding consecutive amino acids 101 to 244 of SEQ ID NO:6.
27. The transformed host cell according to claim 26 , wherein said nucleic acid sequence further comprises at least one additional heterologous nucleic acid sequence.
28. The transformed host cell according to claim 25 , wherein said nucleic acid sequence further comprises at least one additional heterologous nucleic acid sequence.
29. The transformed host cell according to claim 28 , wherein said at least one additional heterologous nucleic acid sequence encodes a heterologous polypeptide.